Contribute Try STAT+ Today

The Japanese drug maker Otsuka has been approved to purchase the assets of bankrupt smart pill maker Proteus Digital Health for $15 million — capping off a spectacular fall for Proteus, which raised close to $500 million and soared to a valuation of $1.5 billion on the promise that its sensor technology could revolutionize how medications are taken and tracked.

The sale, approved on Wednesday by a federal bankruptcy court judge in Delaware after a three-day hearing, overcame the fierce objections of a group of Proteus investors that included the pharma giant Novartis. Those investors opposed Otsuka’s purchase of Proteus because they thought Otsuka, a longtime Proteus investor and partner, was an insider and that Proteus’s assets could go for a higher price had they been divided up and left up for sale for a longer period.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.